tetano
Editor, Senior Moderator
Sci Rep
. 2025 Jul 28;15(1):27441.
doi: 10.1038/s41598-025-06052-3. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19
Mark Berry[SUP] 1 [/SUP], Amanda M Kong[SUP] 2 [/SUP], Roger Paredes[SUP] 3 4 [/SUP], Julie Paone[SUP] 2 [/SUP], Rohan Shah[SUP] 2 [/SUP], Rebecca Taylor[SUP] 2 [/SUP], Essy Mozaffari[SUP] 1 [/SUP], Rikisha Gupta[SUP] 1 [/SUP], Robert L Gottlieb[SUP] 5 6 7 8 [/SUP], Lourdes Mateu[SUP] 4 [/SUP], Mazin Abdelghany[SUP] 1 [/SUP], Jason D Goldman[SUP] 9 10 11 [/SUP], Anand P Chokkalingam[SUP] 1 12 [/SUP]
Affiliations
Long COVID comprises a multisystem syndrome occurring after COVID-19. This retrospective cohort study investigated whether remdesivir given during acute COVID-19 is associated with reduced incidence of Long COVID, including in immunocompromised subgroups. The HealthVerity database of hospital chargemaster data linked to closed claims was queried for patients aged ≥ 12 years hospitalized for ≥ 2 days with COVID-19 between May 1, 2020, and September 30, 2021. Relative risk between remdesivir-exposed and unexposed patients was calculated for 16 individual Long COVID outcomes and a composite of any Long COVID outcome, occurring 90-270 days after hospital admission. Subgroup analyses occurred in immunocompromised patients. Regression models accounted for censoring, competing risks, and treatment assignment weights; statistical inferences were adjusted for multiple comparisons. Among 3,661,303 hospitalized patients, 52,006 with COVID-19 were included; 20,246 (38.9%) were immunocompromised. In the overall and immunocompromised populations, respectively, 33.0% and 29.5% received remdesivir; the composite of ≥ 1 Long COVID outcome occurred in 55.5% and 62.9%. Patients administered remdesivir experienced lower risk of any Long COVID outcome (risk ratio, 0.96; 95% CI 0.94-0.97; adjusted P < 0.001). Risk for several individual Long COVID outcomes was lower in those receiving remdesivir in the overall and immunocompromised populations. In conclusion, exposure to remdesivir was associated with a lower risk of Long COVID.
Keywords: Antiviral therapy; COVID-19; Immunocompromising conditions; Long COVID; Remdesivir.
. 2025 Jul 28;15(1):27441.
doi: 10.1038/s41598-025-06052-3. Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19
Mark Berry[SUP] 1 [/SUP], Amanda M Kong[SUP] 2 [/SUP], Roger Paredes[SUP] 3 4 [/SUP], Julie Paone[SUP] 2 [/SUP], Rohan Shah[SUP] 2 [/SUP], Rebecca Taylor[SUP] 2 [/SUP], Essy Mozaffari[SUP] 1 [/SUP], Rikisha Gupta[SUP] 1 [/SUP], Robert L Gottlieb[SUP] 5 6 7 8 [/SUP], Lourdes Mateu[SUP] 4 [/SUP], Mazin Abdelghany[SUP] 1 [/SUP], Jason D Goldman[SUP] 9 10 11 [/SUP], Anand P Chokkalingam[SUP] 1 12 [/SUP]
Affiliations
- PMID: 40721590
- PMCID: PMC12304269
- DOI: 10.1038/s41598-025-06052-3
Long COVID comprises a multisystem syndrome occurring after COVID-19. This retrospective cohort study investigated whether remdesivir given during acute COVID-19 is associated with reduced incidence of Long COVID, including in immunocompromised subgroups. The HealthVerity database of hospital chargemaster data linked to closed claims was queried for patients aged ≥ 12 years hospitalized for ≥ 2 days with COVID-19 between May 1, 2020, and September 30, 2021. Relative risk between remdesivir-exposed and unexposed patients was calculated for 16 individual Long COVID outcomes and a composite of any Long COVID outcome, occurring 90-270 days after hospital admission. Subgroup analyses occurred in immunocompromised patients. Regression models accounted for censoring, competing risks, and treatment assignment weights; statistical inferences were adjusted for multiple comparisons. Among 3,661,303 hospitalized patients, 52,006 with COVID-19 were included; 20,246 (38.9%) were immunocompromised. In the overall and immunocompromised populations, respectively, 33.0% and 29.5% received remdesivir; the composite of ≥ 1 Long COVID outcome occurred in 55.5% and 62.9%. Patients administered remdesivir experienced lower risk of any Long COVID outcome (risk ratio, 0.96; 95% CI 0.94-0.97; adjusted P < 0.001). Risk for several individual Long COVID outcomes was lower in those receiving remdesivir in the overall and immunocompromised populations. In conclusion, exposure to remdesivir was associated with a lower risk of Long COVID.
Keywords: Antiviral therapy; COVID-19; Immunocompromising conditions; Long COVID; Remdesivir.